| Original language | English (US) |
|---|---|
| Pages (from-to) | 556-562.e4 |
| Journal | Gastroenterology |
| Volume | 163 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2022 |
| Externally published | Yes |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Gastroenterology, Vol. 163, No. 3, 09.2022, p. 556-562.e4.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Multicenter Randomized Controlled Trial of Surveillance Versus Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
T2 - The SURVENT Trial: Study Rationale, Methodology, Innovation, and Implications
AU - SURVENT Trial Consortium
AU - Wani, Sachin
AU - Souza, Rhonda F.
AU - Durkalski, Valerie L.
AU - Serrano, Jose
AU - Hamilton, Frank
AU - Shaheen, Nicholas J.
N1 - Funding Information: The SURVENT trial is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. The organizational structure includes the Executive, Steering, Biorepository, Trial Operations, Protocol, Ancillary Studies, Publications, and Coordinator Committees with active participation from the principal investigators, NIDDK staff, and site investigators. The Clinical Coordinating Center and Central Biorepository is housed at the University of Colorado and the Statistical and Data Coordinating Center at the Medical University of South Carolina. An NIDDK-appointed Data and Safety Monitoring Board and a study-appointed independent medical safety monitor will oversee the safety in the SURVENT trial. The SURVENT trial will be completed at approximately 21 high-volume regional centers in the United States. All eligible subjects will be offered inclusion without any reference to sex or minority status. Funding Information: Funding Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Supported by grants U34DK124174 and 1U01DK129191. The authors are solely responsible for the content of this article. Funding Information: Conflicts of Interest These authors disclose the following: Sachin Wani is a consultant for Exact Sciences, on the advisory board for Cernostics, and receives research support from Lucid , Ambu , and CDx Diagnostics . Nicholas J. Shaheen receives research funding from Medtronic , Steris , Pentax , CDx Diagnostics, Interpace Diagnostics , and Lucid Medical and is a consultant for Cernostics, Phathom Pharmaceuticals , Exact Sciences , and Cook Medical . Rhonda F. Souza is a consultant for Ironwood Pharmaceuticals , Phathom , IsoThrive , CDx Diagnostics, AstraZeneca , and Cernostics and receives research funding from Phathom and Sanofi . The remaining authors disclose no conflicts.
PY - 2022/9
Y1 - 2022/9
UR - http://www.scopus.com/inward/record.url?scp=85135909784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135909784&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2022.05.051
DO - 10.1053/j.gastro.2022.05.051
M3 - Article
C2 - 35679951
AN - SCOPUS:85135909784
SN - 0016-5085
VL - 163
SP - 556-562.e4
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -